Pseudomyxoma peritonei – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pseudomyxoma peritonei – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of Pseudovax, molgramostim and tislelizumab combination therapy for patients with pseudomyxoma peritonei cancer https://clinicaltrials.eu/trial/a-study-of-pseudovax-molgramostim-and-tislelizumab-combination-therapy-for-patients-with-pseudomyxoma-peritonei-cancer/ Wed, 29 Apr 2026 15:06:28 +0000 https://clinicaltrials.eu/trial/a-study-of-pseudovax-molgramostim-and-tislelizumab-combination-therapy-for-patients-with-pseudomyxoma-peritonei-cancer/ This clinical trial focuses on treating patients with Pseudomyxoma Peritonei, a rare type of cancer that primarily affects the abdominal cavity. The study will test a combination of three medications: Pseudovax (a cancer vaccine), Tislelizumab (a medication that helps the immune system fight cancer cells), and Molgramostim (a substance that stimulates the production of white blood cells).

The purpose of this study is to evaluate how safe and well-tolerated these medications are when given in sequence, and to measure how they activate the immune system. Pseudovax will be given as an injection under the skin, while Tislelizumab will be administered through an intravenous infusion (directly into a vein). Molgramostim will also be given as an injection under the skin.

The treatment period will last several months, during which participants will receive regular doses of these medications. Throughout the study, doctors will monitor the participants’ health and measure how their immune system responds to the treatment. They will also track how long participants remain free from disease progression.

]]> Study on Capecitabine and Cyclophosphamide for Patients with Large Pseudomyxoma Peritonei Preparing for Surgery and Chemotherapy https://clinicaltrials.eu/trial/study-on-capecitabine-and-cyclophosphamide-for-patients-with-large-pseudomyxoma-peritonei-preparing-for-surgery-and-chemotherapy/ Wed, 29 Apr 2026 14:59:09 +0000 https://clinicaltrials.eu/trial/study-on-capecitabine-and-cyclophosphamide-for-patients-with-large-pseudomyxoma-peritonei-preparing-for-surgery-and-chemotherapy/ This clinical trial is focused on studying a condition called Pseudomyxoma Peritonei (PMP), which is a rare type of cancer that causes a buildup of mucus in the abdomen. The study involves patients with a high tumor burden, meaning they have a large amount of tumor present. The treatment being tested includes two medications: Capecitabine and Cyclophosphamide. These medications are taken orally in the form of tablets. The purpose of the study is to evaluate how effective this treatment is in helping patients achieve complete removal of the tumor through surgery.

Participants in the study will receive the medications Capecitabine and Cyclophosphamide over a period of six months. The treatment is given before a surgical procedure called cytoreductive surgery, which aims to remove as much of the tumor as possible. This is followed by a special type of chemotherapy called hyperthermic intraperitoneal chemotherapy (HIPEC), which is administered directly into the abdomen to target any remaining cancer cells. The study will monitor the patients’ response to the treatment and the surgery, as well as their overall health and quality of life during and after the treatment.

The trial aims to determine the proportion of patients who achieve complete tumor removal after receiving the treatment. It will also assess the safety and tolerability of the medications, as well as the impact on patients’ quality of life. The study will involve regular check-ups and imaging tests, such as CT scans, to evaluate the size of the tumor and the effectiveness of the treatment. The trial is expected to continue until 2029, with recruitment starting in 2024.

]]>